Skip to main content

MSCopilot - Digital Assessment in Multiple Sclerosis

What is MS?

Multiple Sclerosis is a chronic autoimmune disease, which attacks myelin - the substance that surrounds and insulates the nerve fibers — as well as the nerve fibers themselves.

MS impacts patients' motricity, balance, vision and evolves by relapses. In 85% of cases, patients develop handicaps and a loss of motricity.

More than 2.5 million people worldwide are affected by MS. Its treatment costs are estimated between 15 and 20 billion euros per year in Europe. Currently, the means used to follow and treat MS are not optimized. The patient assessment relies on a score coming from medical gold standards tests / questionnaires (MSFC, EDSS...) hard and lengthy to conduct and presenting several limits.


MSCopilot, an innovation in MS assessment

Ad Scientiam has developed MSCopilot, which innovates in MS self-assessment and aims at becoming THE new market standard.

In addition, several digital functionalities will support patients (symptom checker, adherence, tutorials...)

Self-assessment tests developed were built from the MSFC method, co-created with a board of experts and patients, and validated through large scale clinical trial. They will evaluate vision, cognition, dexterity and walking.

Finally, collected real-world data will allow future analytics studies and continuous improvement of algorithms.


This program has been conducted with the institutional support of Roche France, a medical board of neurologists and leading patients and clinicians associations (French Federation of Neurology, OFSEP, ARSEP)

A Proof-of-Concept study was conducted in 2016 on MSCopilot (TRL 6: System/subsystem model or prototype demonstration in a relevant environment), demonstrating a strong correlation between MSCopilot and MSFC scores.


MSCopilot® was supported by the french program investissement d'avenir

An article about Ad Scientiam in Neurologies

Le Monde Grand Angle published an article about MSCopilot

Ad Scientiam published an article about MSCopilot in revue neurologique

Ad Scientiam présente MSCopilot dans le journal de France Inter : interview de Liouma Tokitsu, Elisabeth Maillart et Yann Le Coz

APMnews: the latest Ad Scientiam software medical device is available on the Google and Apple Stores. It has been developed to improve the monitoring...

Ad Scientiam lance MSCopilot, l'appli pour le suivi de la sclérose en plaques

Ad Scientiam has launched a multi-centric clinical validation study, on 200+ participants, for its multiple sclerosis assessment solution, MSCopilot

Ad Scientiam solution, MSCopilot (Digital self-Assessment for Multiple Sclerosis), was...

2 weeks ago, Ad Scientiam won the 2017 Digital Innovation Competition in the Health category.
It will allow us to access a financing by the Programme...

Driven by the wish to develop relevant and useful mobile applications, Ad Scientiam closely collaborates with patient advocacy groups at every step of...